primary progressive MS (PPMS)

Using an implantable scaffold to collect immune cells in mice, researchers have gained insights into the immunological mechanisms driving primary progressive multiple sclerosis (PPMS). Based on the findings, the scientists developed a treatment strategy to block specific inflammatory molecules, which eased MS severity in the mouse model. The study,…

Gender and age at the onset of disease don’t seem to have a clinically relevant impact on disability progression in people with primary progressive multiple sclerosis (PPMS), according to a recent study in Argentina. Disease progression, based on the Expanded Disability Status…

A global Phase 2 clinical trial investigating the oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of multiple sclerosis (MS) has reached full enrollment, the treatment’s developer, Immunic Therapeutics, reports. Called CALLIPER (NCT05054140), the trial is assessing whether the neuroprotective effects of vidofludimus calcium seen in…

Cognitive dysfunction in patients with multiple sclerosis (MS) is predictive of worse outcomes, including clinical progression of the disease and a higher risk of mortality, according to a new study. “This review revealed that cognitive dysfunction … was associated with higher odds of transitioning from [a] relapsing–remitting course to…

FDA Will Review New Drug Application of Diroximel Fumarate for Relapsing Forms of MS The good news: Another disease-modifying therapy (DMT) has taken a step toward approval in the U.S. The discouraging news: It’s another DMT designed to treat relapsing forms of multiple sclerosis. More than a…

My column last week was a recap of my journey to a primary progressive multiple sclerosis (PPMS) diagnosis. This week’s column continues that theme by showing a glimpse of what it is like to live with PPMS on a daily basis. To say that having a disability like…

I have lived with the diagnosis of primary progressive multiple sclerosis (PPMS) for almost eight years. For many years prior to that diagnosis, I was confused by what could be causing my abnormal gait, extreme fatigue, blurred vision, and trouble concentrating. During that time, I completed many diagnostic tests, dealt…

Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based on a recommendation by the Data Monitoring Committee (DMC) that is supervising the clinical trials after cardiovascular events, none of which were fatal,…